Herriot Tabuteau, Axsome CEO (Owen Hoffmann/Patrick McMullan via Getty Images)

Ax­some's long de­layed de­pres­sion drug is back up for la­bel dis­cus­sions at the FDA, trig­ger­ing a big spike in the share price

Ax­some’s on-and-off quest to ob­tain an FDA ap­proval for their de­pres­sion drug AXS-05 is back on again.

Af­ter the mar­kets closed on Mon­day, the biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.